

Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

Market Research Report | 2025-03-25 | 160 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.

Report Includes

- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

with a look into the patent expirations in the industry

- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca

Executive Summary

Summary:

The global market for CAR T-cell therapy is expected to grow from \$4.6 billion in 2024 and projected to reach \$25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.

CAR T-cell therapy is a novel method for treating hematologic tumors that were previously considered incurable and have been developed by modifying a patient's T cells to express a chimeric antigen receptor (CAR) unique to a tumor antigen (TA). The foundation of this treatment is the CAR's ability to attach to antigens, which results in a strong T-cell activation and anti-tumor response. Tisagenlecleucel was the first FDA-licensed CAR T-cell therapy authorized in 2017 for treating acute lymphoblastic leukemia in children and young adults.

CAR T-cell therapy holds a huge potential benefit, due to its being tailored to each patient's needs. To target and eliminate cancer cells, T cells are extracted from the patient, genetically altered in the lab to produce CARs on their surface and reintroduced into the patient. CAR T-cell-based treatments have attracted much interest in solid tumors because of their remarkable effectiveness in hematological malignancies. There are now six autologous CAR T-cell treatments that have received FDA approval and are used to treat different types of blood cancer in the U.S. CAR T-cell treatments are being studied in 1,439 clinical studies worldwide in addition to these commercially available products.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

Market and Technology Background

A Brief History of CAR T-Cell Therapy

FDA Product Approvals

Other CAR T-Cell Therapies

Clinical Applications of CAR T-Cell Therapy

Adoptive Cell Transfer (ACT) Technologies

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Increasing Incidence of Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Growing Investments and Funding in CAR T-Cell Therapy Research

Robust R&D Pipeline

Advances in Genetic Engineering

Market Restraints

Complex Legislative and Regulatory Procedures

Alternative Products from Competitors

Market Opportunities

Growing Significance of Precision Medicine

Expanding Applications for CAR T-Cell Therapy

Market Challenges

Complex Manufacturing and Supply Chain

Reimbursement Challenges for CAR T-Cell Therapy

Chapter 4 Emerging Technologies and Clinical Trials

Introduction

Clinical Trials Being Conducted Globally

Distribution of CAR T-Cell Clinical Trials in China

Chapter 5 Market Segmentation Analysis

Key Takeaways

Segmentation Breakdown

Global Market for CAR T-Cell Therapy, by Product

Yescarta

Kymriah

Tecartus

Abecma

Breyanzi

Carvykti

Global Market for CAR T-Cell Therapy, by Indication

Geographic Breakdown

Global Market for CAR T-Cell Therapy, by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 6 Patent Review and New Developments

Introduction

Anticipated Increase in Patent Litigation on Customized Patient Treatments

Company-specific Intellectual Property and Patent Information

Amgen

Avacta Life Sciences Ltd.

Bluebird Bio

Celgene Corp.

Cellectis

Celyad SA

Editas Medicine Inc.

Eureka Therapeutics Inc.

iCell Gene Therapeutics

Juno Therapeutics Inc. (A Celgene Co.)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Noile-Immune Biotech
Novartis AG
Chapter 7 Competitive Intelligence
Ranking of Leading Players
Strategic Considerations
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

Market Research Report | 2025-03-25 | 160 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-06-24
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com